Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Zhang, Ge ^a   Miyake, Makito ^a   Lawton, Adrienne ^b   Goodison, Steve ^a,c,d   Rosser, Charles J ^a,c,e  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b ORLANDO HEALTH   (United States)

^c Nonagen Bioscience Corp   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

Angiogenesis; Apoptosis; Cancer; Invasion; MMP 10

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; GELATINASE A; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA; STROMELYSIN 2;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CANCER; CARCINOGENESIS; CELL FUNCTION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; UPREGULATION; UTERINE CERVIX TUMOR; BIOSYNTHESIS; BLADDER TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

APOPTOSIS; CELL MOVEMENT; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MATRIX METALLOPROTEINASE 10; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; RNA, SMALL INTERFERING; URINARY BLADDER NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

EID: 84900861654     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-310     Document Type: Article

References (43)

1. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Canc 2003, 89:1817-1821.
2. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174. 10.1038/nrc745, 11990853.
3. Madlener M, Mauch C, Conca W, Brauchle M, Parks WC, Werner S. Regulation of the expression of stromelysin-2 by growth factors in keratinocytes: implications for normal and impaired wound healing. Biochem J 1996, 320:659-664. 1217980, 8973581.
4. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003, 253:269-285. 10.1023/A:1026028303196, 14619979.
5. Krampert M, Bloch W, Sasaki T, Bugnon P, Rülicke T, Wolf E, Bloch W, Sasaki T, Bugnon P, Rülicke T, Wolf E. Activities of the matrix metalloproteinase stromelysin-2 (MMP-10) in matrix degradation and keratinocyte organization in wounded skin. Mol Biol Cell 2004, 15:5242-5254. 10.1091/mbc.E04-02-0109, 532007, 15371548.
6. Aung PP, Oue N, Mitani Y, Nakayama H, Yoshida K, Noguchi T, Bosserhoff AK, Yasui W. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene 2006, 25:2546-2557. 10.1038/sj.onc.1209279, 16331256.
7. Eck M, Schmausser B, Scheller K, Brändlein S, Müller-Hermelink HK. Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 2003, 134:508-515. 10.1111/j.1365-2249.2003.02305.x, 1808898, 14632759.
8. Seargent JM, Loadman PM, Martin SW, Naylor B, Bibby MC, Gill JH. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 2005, 65:815-820. 10.1016/j.urology.2004.11.016, 15833553.
9. Mathew R, Khanna R, Kumar R, Mathur M, Shukla NK, Ralhan R. Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Canc Detect Prev 2002, 26:222-228.
10. Kerkelä E, Ala-aho R, Lohi J, Grénman R, M-Kähäri V, Saarialho-Kere U. Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers. Br J Canc 2001, 84:659-669.
11. Zhang X, Zhu S, Luo G, Zheng L, Wei J, Zhu J, Hu S. Expression of MMP-10 in lung cancer. Anticancer Res 2007, 27:2791-2795.
12. Miyake M, Goodison S, Giacoia EG, Rizwani W, Ross S, Rosser CJ. Influencing factors on the NMP-22 urine assay: an experimental model. BMC Urol 2012, 12:23. doi:10.1186/1471-2490-12-23, 10.1186/1471-2490-12-23, 3480828, 22928931.
13. Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J, Abraham JM, Meltzer SJ, Sato F. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Canc Res 2008, 68:3214-3218.
14. Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 2008, 68:1223-1231. 10.1002/pros.20788, 18465755.
15. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
16. Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol 2011, 29:421-429. 10.1016/j.urolonc.2009.04.009, 19576799.
17. Namiki K, Goodison S, Porvasnik S, Allan RW, Iczkowski KA, Urbanek C, Reyes L, Sakamoto N, Rosser CJ. Persistent exposure to Mycoplasma induces malignant transformation of human prostate cells. PLoS One 2009, 4:e6872. doi:10.1371/journal.pone.0006872, 10.1371/journal.pone.0006872, 2730529, 19721714.
18. Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Canc Ther 2007, 6:101-111.
19. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S, Gasparini G. Tumor angiogenesis: a new significant and independent prognostic indicator in early stage breast carcinoma. J Natl Canc Inst 1992, 84:1875-1887.
20. Urquidi V, Goodison S, Cai Y, Sun Y, Rosser CJ. A candidate molecular biomarker panel for the detection of bladder cancer. Canc Epidemiol Biomarkers Prev 2012, 21:2149-2158.
21. Goodison S, Chang M, Dai Y, Urquidi V, Rosser CJ. A multi-analyte assay for the non-invasive detection of bladder cancer. PLoS One 2012, 7(10):e47469. 10.1371/journal.pone.0047469, 3477150, 23094052.
22. Rosser CJ, Ross S, Chang M, Dai Y, Mengual L, Zhang G, Kim J, Urquidi V, Alcaraz A, Goodison S, Rosser CJ. Multiplex protein signature for the detection of bladder cancer in voided urine samples. J Urol 2013, 5347:4581-4583.
23. Zucker S, Cao J, Chen WT. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000, 19:6642-6650. 10.1038/sj.onc.1204097, 11426650.
24. Meyer E, Vollmer JY, Bovey R, Stamenkovic I. Matrix metalloproteinases 9 and 10 inhibit protein kinase C-potentiated, p53-mediated apoptosis. Canc Res 2005, 65:4261-4272.
25. Vázquez-Ortíz G, Ciudad CJ, Piña P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA, Salamanca F, Peralta-Rodriguez R, Rangel A, Salcedo M. Gene identification by cDNA arrays in HPV-positive cervical cancer. Arch Med Res 2005, 36:448-458. 10.1016/j.arcmed.2005.04.016, 16099320.
26. Liu H, Qin YR, Bi J, Guo A, Fu L, Guan XY. Overexpression of matrix metalloproteinase 10 is associated with poor survival in patients with early stage of esophageal squamous cell carcinoma. Dis Esophagus 2012, 25:656-663. 10.1111/j.1442-2050.2011.01284.x, 22121946.
27. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516. 10.1146/annurev.cellbio.17.1.463, 2792593, 11687497.
28. Mishra DK, Sakamoto JH, Thrall MJ, Baird BN, Blackmon SH, Ferrari M, Kurie JM, Kim MP. Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One 2012, 7:e45308. doi:10.1371/journal.pone.0045308, 10.1371/journal.pone.0045308, 3444466, 23028922.
29. Rossi MR, Masters JR, Park S, Todd JH, Garrett SH, Sens MA, Somji S, Nath J, Sens DA. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ Health Perspect 2001, 109:801-808. 10.1289/ehp.01109801, 1240407, 11564615.
30. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol 2001, 13:534-540. 10.1016/S0955-0674(00)00248-9, 11544020.
31. Rijken DC. Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Baillieres Clin Haematol 1995, 8:291-312. 10.1016/S0950-3536(05)80269-0, 7549064.
32. Pyke C, Kristensen P, Ralfkiaer E, Eriksen J, Danø K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Canc Res 1991, 51:4067-4071.
33. Stefansson S, Haudenschild CC, Lawrence DA. Beyond fibrinolysis: the role of plasminogen activator inhibitor-1 and vitronectin in vascular wound healing. Trends Cardiovasc Med 1998, 8:175-180. 10.1016/S1050-1738(98)00003-6, 21235930.
34. Harbeck N, Kates RE, Schmitt M, Gauger K, Kiechle M, Janicke F, Thomassen C, Look MP, Foekens JA. Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin Breast Canc 2004, 5:348-352.
35. Duffy MJ. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin Chem 2002, 48:1194-1197.
36. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002, 26:767-771. 10.1007/s00268-002-4050-8, 11965442.
37. Pavey SJ, Hawson GA, Marsh NA. Impact of the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinolysis 2001, 12:51-58. 10.1097/00001721-200101000-00008, 11229827.
38. Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del Monte G, Guadagni F, Roselli M. Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 2009, 124:403-408. 10.1016/j.thromres.2009.02.014, 19351570.
39. Bashar H, Urano T, Fukuta K, Pietraszek MH, Hata M, Suzuki K, Suzuki K, Kawabe K, Takada Y, Takada A. Plasminogen activators and plasminogen activator inhibitor 1 in urinary tract cancer. Urol Int 1994, 52:4-8. 10.1159/000282560, 8140679.
40. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Algaba F, Vicente-Rodriguez J. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164:680-684. 10.1016/S0022-5347(05)67280-1, 10954628.
41. Fang H, Placencio VR, DeClerck YA. Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Canc Inst 2012, 104:1470-1484.
42. Wilkins-Port CE, Ye Q, Mazurkiewicz JE, Higgins PJ. TGF-beta1 + EGF-initiated invasive potential in transformed human keratinocytes is coupled to a plasmin/MMP-10/MMP-1-dependent collagen remodeling axis: role for PAI-1. Canc Res 2009, 69:4081-4091.
43. Freytag J, Wilkins-Port CE, Higgins CE, Carlson JA, Noel A, Foidart JM, Higgins SP, Samarakoon R, Higgins PJ. PAI-1 regulates the invasive phenotype in human cutaneous squamous cell carcinoma. J Oncol 2009, 2009:963209. 2829771, 20204159.